secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001493152-24-010192
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics appoints Dr. James Kelly as CMO to lead Phase II concussion trial
---------------------------------------------------------------------------

- Dr. Kelly will serve as CMO under an independent contractor agreement at $400/hour for 20 hours/month.
- He will oversee the Phase II trial of ONP-002, an intranasal NCE for mild traumatic brain injury.
- ONP-002 completed a 40-patient Phase I safety study; a 69 million annual concussion market cited.
- Dr. Kelly previously led the Marcus Institute for Brain Health and founded the NICoE at Walter Reed.
- Company is completing GMP drug manufacturing for the Phase II trial initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224010192/0001493152-24-010192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224010192/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer